Why Are Investors Heading For The Exits In These Five Stocks Today?

In the first few months of the Jack Dorsey-as-CEO era, Twitter Inc (NYSE:TWTR) shares haven’t done well, as they are only 14% above their 52 week low and have inched down by 2.8% today. Although it remains the first place for hundreds of millions of people around the world to get the latest news that matter, Twitter Inc (NYSE:TWTR) has struggled to monetize its audience. The company’s earnings results have disappointed the bulls in recent quarters and given its current lineup of products, it also seems Twitter’s U.S. MAU growth is a thing of the past. Many investors hope Twitter introduces new products that can bring more people into the fold and better monetize the service. Our data show that the smart money has been more cautious about Twitter, with only 27 funds long the stock at the end of September, versus 47 funds at the end of June.

Lastly, Bluebird bio Inc (NASDAQ:BLUE) dropped by 36% in afternoon trading, on the back of the company releasing disappointing results for its gene therapy in sickle cell disease and beta thalassemia candidate, LentiGlobin BB305. According to the data from a Phase 1 sickle cell disease trial, patients have not responded as quickly as expected to the drug, with the proportion of anti-sickling hemoglobin at 17% and 16% in two patients three months post infusion, versus the 30% needed to have a clinical effect. The data also showed disappointing results in another trial for a subtype of beta thalassemia. Andreas Halvorsen’s Viking Global owned 615,557 shares of Bluebird bio at the end of September.

Disclosure:None